Contineum Therapeutics, INC 8-K filings

Contineum Therapeutics reported Q2 2026 financial results, highlighting progress in its PROPEL-IPF trial and affirming its cash runway through mid-2029.

Contineum Therapeutics, Inc. has updated its corporate presentation on July 13, 2026, detailing business and strategic updates, including progress on its lead drug candidates PIPE-791 and PIPE-307.

Contineum Therapeutics stockholders re-elected three Class II directors and ratified the appointment of Ernst & Young LLP as the independent auditor for 2026.

Contineum Therapeutics reported Q1 2026 financial results, highlighting positive topline data from a chronic pain trial and affirming key clinical development milestones for its lead drug candidates.

Contineum Therapeutics announced positive topline results from its Phase 1b trial of PIPE-791, demonstrating safety and efficacy signals in chronic pain patients.

Contineum Therapeutics increased its at-the-market equity offering to $100 million, reported fourth-quarter 2025 financial results, and provided updates on its clinical pipeline, including the initiation of a Phase 2 IPF trial.

Contineum Therapeutics' Board approved a new 2026 Employment Inducement Equity Incentive Plan to attract new talent.

Contineum Therapeutics, a clinical-stage biopharmaceutical company, announced the pricing of an upsized public offering of 7.35 million shares of Class A common stock at $12.25 per share, raising approximately $84.2 million in net proceeds.

Contineum Therapeutics has initiated a global Phase 2 clinical trial for PIPE-791 to treat idiopathic pulmonary fibrosis, with results expected by June 2028.

Contineum Therapeutics reported that its Phase 2 PIPE-307 VISTA trial for relapsing-remitting multiple sclerosis did not meet its primary or secondary efficacy endpoints.

Contineum Therapeutics reported Q3 2025 financial results, affirmed key clinical development milestones, and extended its cash runway through 2028.

Contineum Therapeutics announced positive topline data from its PIPE-791 Phase 1b PET trial, demonstrating high LPA1 brain receptor occupancy and a consistent safety profile.

Contineum Therapeutics reported its second-quarter 2025 financial results and updated key clinical development milestones, including anticipated topline data for PIPE-307 and PIPE-791, alongside a cash runway extension through 2027.

Contineum Therapeutics, Inc. announced the results of its 2025 Annual Meeting of Stockholders, where three Class I directors were elected and Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Contineum Therapeutics announced its Q1 2025 financial results, reporting a net loss of $16.0 million and affirming key clinical development milestones, with a cash runway projected through 2027.

Contineum Therapeutics has appointed Timothy Watkins as its Chief Medical Officer and Head of Development, effective immediately.

Contineum Therapeutics appoints Diego Miralles, M.D., to its Board of Directors, effective March 14, 2025.

Contineum Therapeutics announces its fourth-quarter 2024 financial results, highlighting key clinical development milestones and a cash runway projected through 2027.

Contineum Therapeutics announced its Q3 2024 financial results, highlighting clinical trial progress for PIPE-307 and PIPE-791, and a strong cash position of $214 million.

Contineum Therapeutics announced its second quarter 2024 financial results, highlighted by a strong cash position and key appointments to its board and management team.

Contineum Therapeutics announced its second quarter 2024 financial results, highlighted by a strong cash position and advancements in clinical trials and leadership.

Contineum Therapeutics has appointed Sarah Boyce to its Board of Directors, effective June 24, 2024, where she will also chair the Nominating and Corporate Governance Committee.

Contineum Therapeutics has adopted a new executive severance plan and mutual arbitration agreements for its named executive officers and certain key employees.

Contineum Therapeutics has appointed Troy Ignelzi to its Board of Directors and as Chair of the Audit Committee, effective immediately.

Contineum Therapeutics announced its first quarter 2024 financial results, highlighted by a successful IPO and advancements in its clinical programs.

Contineum Therapeutics has filed amended and restated certificate of incorporation and bylaws in connection with the closing of its initial public offering.